Country: Singapore
Language: English
Source: HSA (Health Sciences Authority)
Clostridium Botulinum Toxin Type A
HYPHENS PHARMA PTE. LTD.
M03AX01
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Clostridium Botulinum Toxin Type A 100 Units/vial
INTRAMUSCULAR
Prescription Only
Daewoong Pharmaceutical Co., Ltd.
ACTIVE
2023-01-20
1 / 8 PACKAGE INSERT 1. NAME OF THE MEDICINAL PRODUCT NABOTA Powder for Solution for Injection 100units/vial 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains: - Active ingredient: Clostridium botulinum toxin type A – 100 Units - Stabilizing agent: Human serum albumin – 0.5mg - Isotonic agent: Sodium chloride – 0.9mg 3. PHARMACEUTICAL FORM It appears as a white to yellowish, vacuum-dried powder for injection in a colourless and transparent vial. It should become clear transparent liquid when dissolved in the diluent (physiological saline solution). 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Temporary improvement in the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows) associated with corrugator muscle and/or procerus muscle activities, in adults below 65 years of age. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For intramuscular use only. Reconstitute by diluting with preservative-free, sterile saline solution to make 100U/2.5mL (4U/0.1mL). Using a sterile 30-gauge needle, inject a dose of 0.1mL into each of the 5 injection sites: 2 injections in each corrugator muscle and 1 injection in the procerus muscle for a total dose of 20 Units. Physical manipulation (such as rubbing) of the injection site in the immediate post-administration period should be avoided. _ _ In order to reduce the complication of ptosis, injections near the levator palpebrae superioris muscle must be avoided, particularly in patients with larger brow-depressor complexes (depressor supercilii). Injections into inner corrugators muscle and central eyebrow should be placed at least 1 cm above the bony supraorbital ridge. Careful attention should be paid to avoid injection of this product into the blood vessel. The thumb or index finger should be placed firmly below the orbital rim in order to prevent extravasation below the orbital rim. The needle should be oriented superiorly and medially during the injection and careful attention should be paid to inject accurate volume. 2 / 8 Gla Read the complete document